Aller au contenu principal
Fermer
  2. Aide
  2. Aide

BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY
information fournie par Boursorama CP 10/08/2026 à 07:00
Ajoutez Boursorama à vos sources préférées

Paris (France) and Cambridge (Massachusetts, U.S.), August 10, 2026, at 07:00am CET – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a biotechnology company pioneering the development of transformative therapies for longevity, today announces that it has received approval from Brazil’s National Health Surveillance Agency (ANVISA) to begin the Phase 2 OBA clinical trial for obesity in Brazil and shares the outlook for its drug candidate BIO101 in obesity. The authorization follows regulatory approvals already obtained in the United States and Europe, confirming Biophytis’ ability to conduct multi-regional clinical development in compliance with the requirements of major health authorities.

Valeurs associées

BIOPHYTIS
0,0287 EUR Euronext Paris -6,51%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
HAFFNER ENERGY
0,556 +7,13%
Pétrole Brent
89,57 +1,92%
2CRSI
27,68 -3,55%
CAC 40
8 705,66 -0,23%
INNATE PHARMA
1,828 -0,22%
Chargement...

Pages les plus populaires

L'offre BoursoBank